Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

21. Cardiovascular Disease: Tailored Pharmacy-based Interventions to Improve Medication Adherence

disease prevention medications at least 80% of the time. The proportion of patients considered adherent increased by a median of 6.9 percentage points (an increase of ≈ 9.9%) The remaining 21 studies used various tools to measure adherence (e.g., objective provider counts or records, self-report) and reported generally favorable results. Cardiovascular Disease Risk Conditions A subset of 17 studies evaluated intervention effects on blood pressure control and lipid control. There was a median increase (...) " or "cardiovascular diseases").mp. 33. ("cerebrovascular disease" or "cerebrovascular diseases" or "cerebrovascular event" or "cerebrovascular events" or "angina" or "coronary disease" or "coronary artery disease" or "ischemia" or "myocardial ischemic preconditioning").mp. 34. ("transient ischemic attack" or "brain hypoxia ischemia" or "myocardial ischemia" or "heart diseases" or "myocardial infarction" or "stroke" or "cerebrovascular disorders" or "basal ganglia cerebrovascular disease").mp. 35. (angina pectoris

2020 Community Preventive Services Task Force

22. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. (Abstract)

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. Lipoprotein(a) levels are genetically determined and, when elevated, are a risk factor for cardiovascular disease and aortic stenosis. There are no approved pharmacologic therapies to lower lipoprotein(a) levels.We conducted a randomized, double-blind, placebo-controlled, dose-ranging trial involving 286 patients with established cardiovascular disease and screening lipoprotein(a) levels of at least 60 mg per deciliter (150 nmol (...) 0.003 to <0.001). There were no significant differences between any APO(a)-LRx dose and placebo with respect to platelet counts, liver and renal measures, or influenza-like symptoms. The most common adverse events were injection-site reactions.APO(a)-LRx reduced lipoprotein(a) levels in a dose-dependent manner in patients who had elevated lipoprotein(a) levels and established cardiovascular disease. (Funded by Akcea Therapeutics; ClinicalTrials.gov number, NCT03070782.).Copyright © 2020

2020 NEJM

23. Healthy lifestyle and life expectancy free of cancer, cardiovascular disease, and type 2 diabetes: prospective cohort study. Full Text available with Trip Pro

Healthy lifestyle and life expectancy free of cancer, cardiovascular disease, and type 2 diabetes: prospective cohort study. To examine how a healthy lifestyle is related to life expectancy that is free from major chronic diseases.Prospective cohort study.The Nurses' Health Study (1980-2014; n=73 196) and the Health Professionals Follow-Up Study (1986-2014; n=38 366).Five low risk lifestyle factors: never smoking, body mass index 18.5-24.9, moderate to vigorous physical activity (≥30 minutes (...) /day), moderate alcohol intake (women: 5-15 g/day; men 5-30 g/day), and a higher diet quality score (upper 40%).Life expectancy free of diabetes, cardiovascular diseases, and cancer.The life expectancy free of diabetes, cardiovascular diseases, and cancer at age 50 was 23.7 years (95% confidence interval 22.6 to 24.7) for women who adopted no low risk lifestyle factors, in contrast to 34.4 years (33.1 to 35.5) for women who adopted four or five low risk factors. At age 50, the life expectancy free

2020 BMJ

24. Cardiovascular disease prevention: applying All Our Health

Cardiovascular disease prevention: applying All Our Health Cardiovascular disease prevention: applying All Our Health - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Cardiovascular disease prevention: applying All Our Health Evidence and guidance to help healthcare (...) professionals to prevent heart attacks, strokes and dementia and to improve cardiovascular health. Published 9 January 2019 Last updated 16 December 2019 — From: Documents HTML Details This resource helps: front-line health professionals team leaders or managers senior or strategic leaders to prevent ill health and promote wellbeing as part of their everyday practice. We also recommend important actions that managers and staff holding strategic roles can take. View the full range of topics. Published 9

2020 Public Health England

25. Development and validation of a cardiovascular risk score for patients in the community after acute coronary syndrome

Development and validation of a cardiovascular risk score for patients in the community after acute coronary syndrome Development and Validation of a Cardiovascular Risk Score for Patients in the Community After Acute Coronary Syndrome - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily (...) : Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Heart Actions 2019 Dec 10 [Online ahead of print] Development and Validation of a Cardiovascular Risk Score for Patients in the Community After Acute Coronary Syndrome , , , , , , , , Affiliations Expand Affiliations 1 Epidemiology & Biostatistics, University of Auckland, Auckland, New Zealand

2020 EvidenceUpdates

26. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China Full Text available with Trip Pro

. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients. Conclusion Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart. Introduction During the past two decades, the outbreak and prevalence of severe acute (...) of coronaviruses. Trends Microbiol 24:490–502 19. Cui J, Li F, Shi ZL (2019) Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17:181–192 20. Chan JW, Ng CK, Chan YH, Mok TY, Lee S, Chu SY, Law WL, Lee MP, Li PC (2003) Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 58:686–689 21. Hu S, Gao R, Liu L, Zhu M, Wang W, Wang Y, Wu Z, Li H, Gu D, Yang Y (2019) Summary of the 2018 report on cardiovascular diseases

2020 Covid-19 Ad hoc papers

27. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic Full Text available with Trip Pro

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic | JACC: Journal of the American College of Cardiology Advertisement User menu Source Search for this keyword Search Source Search for this keyword Search Journal of the American College of Cardiology DOI: 10.1016/j.jacc (...) .2020.03.031 JACC State-of-the-Art Review Just Accepted Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic Elissa Driggin , Mahesh V. Madhavan , Behnood Bikdeli , Taylor Chuich , Justin Laracy , Giuseppe Bondi-Zoccai , Tyler S. Brown , Caroline Der Nigoghossian , David A. Zidar , Jennifer Haythe , Daniel Brodie , Joshua A. Beckman , Ajay J. Kirtane , Gregg W. Stone , Harlan M. Krumholz and Sahil A. Parikh Author

2020 American College of Cardiology

28. CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic

, and strict measures to limit infection spread within the hospital and to healthcare workers. 1. Risk assessment Downloaded from http://ahajournals.org by on April 10, 202010.1161/CIRCULATIONAHA.120.047011 7 The purpose of risk assessment is to carefully weigh the relative advantages and disadvantages of treating cardiovascular disease all while preventing the risk of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) transmission. During the period of epidemic, under the premise of minimizing (...) CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic 10.1161/CIRCULATIONAHA.120.047011 1 CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic Running Title: Han et al.; Consensus on Managing CVD during COVID-19 Epidemic Yaling Han, MD, FACC, FAHA, Chair 1 ; Hesong Zeng, MD, co-chair 2 ; Hong Jiang, MD, FACC, co

2020 Covid-19 Ad hoc guidelines

29. COVID-19 and Cardiovascular Disease Patients

disease Reference - Cardiovascular presentations acute cardiovascular presentations associated with COVID-19 may include acute myocardial injury without obstructive coronary artery disease which may present with elevated troponin with or without additional symptoms arrhythmias such as atrial arrhythmias ventricular tachycardia ventricular fibrillation acute coronary syndrome (ST-segment elevation myocardial infraction [STEMI] or non-ST segment elevation myocardial infarction [NSTEMI]) with obstructive (...) ischemia and nonischemic myocardial processes may occur in patients with severe respiratory infection and hypoxia, especially if acute respiratory distress syndrome (ARDS) elevated troponin levels can be present in patients with renal insufficiency due to delayed excretion, especially if advanced disease Reference - cardiovascular complications may occur due to various mechanisms including direct myocardial injury resulting from binding of SARS-CoV-2 virus to angiotensin-converting enzyme 2 (ACE2

2020 DynaMed Plus

30. Implementation of interventions to reduce preventable hospital admissions for cardiovascular or respiratory conditions: an evidence map and realist synthesis Full Text available with Trip Pro

Implementation of interventions to reduce preventable hospital admissions for cardiovascular or respiratory conditions: an evidence map and realist synthesis Implementation of interventions to reduce preventable hospital admissions for cardiovascular or respiratory conditions: an evidence map and realist synthesis Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found (...) . Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Factors facilitating implementation of interventions to reduce avoidable admissions for cardiovascular and respiratory conditions can be identified at a patient, general practitioner and health system level. {{author}} {{($index , & . Duncan Chambers * , Anna Cantrell, Andrew Booth School

2020 NIHR HTA programme

31. Association between ambient fine particulate pollution and hospital admissions for cause specific cardiovascular disease: time series study in 184 major Chinese cities. Full Text available with Trip Pro

Association between ambient fine particulate pollution and hospital admissions for cause specific cardiovascular disease: time series study in 184 major Chinese cities. To estimate the risks of daily hospital admissions for cause specific major cardiovascular diseases associated with short term exposure to ambient fine particulate matter (aerodynamic diameter ≤2.5 μm; PM2.5) pollution in China.National time series study.184 major cities in China.8 834 533 hospital admissions for cardiovascular (...) specific associations between PM2.5 and cardiovascular admissions, and random effects meta-analysis used to combine the city specific estimates.Over the study period, a mean of 47 hospital admissions per day (standard deviation 74) occurred for cardiovascular disease, 26 (53) for ischaemic heart disease, one (five) for heart failure, two (four) for heart rhythm disturbances, 14 (28) for ischaemic stroke, and two (four) for haemorrhagic stroke. At the national average level, an increase of 10 μg/m3

2019 BMJ

32. Birth month, birth season, and overall and cardiovascular disease mortality in US women: prospective cohort study. Full Text available with Trip Pro

Birth month, birth season, and overall and cardiovascular disease mortality in US women: prospective cohort study. To evaluate the associations between birth month, birth season, and overall and cardiovascular disease mortality, and to examine the role of familial and socioeconomic factors in these associations.Prospective cohort study.Nurses' Health Study, established in 1976, an ongoing prospective cohort study in the United States.Female registered nurses who reported information on date (...) of birth at study enrolment (n=116 911, 1976-2014, followed for 38 years).Birth month and astronomical birth season (based on solstices and equinoxes as boundaries of the season categories).Age and various multivariable adjusted hazard ratios and 95% confidence intervals for the association between birth months (using November as the reference), astronomical birth season (using autumn as the reference), and overall and cardiovascular disease specific mortality were assessed using Cox proportional

2019 BMJ

33. Altered Risk for Cardiovascular Events With Changes in the Metabolic Syndrome Status: A Nationwide Population-Based Study of Approximately 10 Million Persons. (Abstract)

Altered Risk for Cardiovascular Events With Changes in the Metabolic Syndrome Status: A Nationwide Population-Based Study of Approximately 10 Million Persons. Population-scale evidence for the association between dynamic changes in metabolic syndrome (MetS) status and alterations in the risk for major adverse cardiovascular events (MACE) is lacking.To investigate whether recovery from or development of MetS in a population is associated with an altered risk for MACE.Nationwide cohort study.An

2019 Annals of Internal Medicine

34. Maternal diabetes during pregnancy and early onset of cardiovascular disease in offspring: population based cohort study with 40 years of follow-up. Full Text available with Trip Pro

Maternal diabetes during pregnancy and early onset of cardiovascular disease in offspring: population based cohort study with 40 years of follow-up. To evaluate the associations between maternal diabetes diagnosed before or during pregnancy and early onset cardiovascular disease (CVD) in offspring during their first four decades of life.Population based cohort study.Danish national health registries.All 2 432 000 liveborn children without congenital heart disease in Denmark during 1977-2016 (...) . Follow-up began at birth and continued until first time diagnosis of CVD, death, emigration, or 31 December 2016, whichever came first.Pregestational diabetes, including type 1 diabetes (n=22 055) and type 2 diabetes (n=6537), and gestational diabetes (n=26 272).The primary outcome was early onset CVD (excluding congenital heart diseases) defined by hospital diagnosis. Associations between maternal diabetes and risks of early onset CVD in offspring were studied. Cox regression was used to assess

2019 BMJ

35. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis Full Text available with Trip Pro

Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular risk irrespective of age, but the evidence is less strong for older patients.This prespecified analysis from ODYSSEY OUTCOMES compared the effect of alirocumab vs. placebo in 18 924 patients with recent acute coronary syndrome (ACS) according to age. We examined the effect of assigned (...) treatment on occurrence of the primary study outcome, a composite of coronary heart disease death, myocardial infarction, ischaemic stroke, or unstable angina requiring hospitalization [major adverse cardiovascular event (MACE)] and all-cause death. Relative risk reductions were consistent for patients ≥65 vs. <65 years for MACE [hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.68-0.91 vs. 0.89, 0.80-1.00; Pinteraction = 0.19] and all-cause death [HR 0.77, 0.62-0.95 vs. 0.94, 0.77-1.15

2019 EvidenceUpdates

36. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association

Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search December 2019 November 2019 October 2019 September 2019 August 2019 July 2019 June 2019 May (...) 2019 April 2019 March 2019 February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association , MD, MSc, FAHA, Chair , MD, Vice Chair , PhD , MD, MPH, FAHA , MD , MD, MSc , MD , MS , MD, FAHA , MD, MS Matthew J. Feinstein

2019 American Heart Association

37. Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. (Abstract)

Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. Recent guidelines endorse using history of menopause before age 40 years to refine atherosclerotic cardiovascular disease risk assessments among middle-aged women. Robust data on cardiovascular disease risk in this population are lacking.To examine the development of cardiovascular diseases and cardiovascular risk factors in women with natural and surgical menopause before age 40 years.Cohort study (UK (...) , +5.57/1000 woman-years [95% CI, 2.41-8.73]; P < .001). For the primary outcome, natural and surgical premature menopause were associated with hazard ratios of 1.36 (95% CI, 1.19-1.56; P < .001) and 1.87 (95% CI, 1.36-2.58; P < .001), respectively, after adjustment for conventional cardiovascular disease risk factors and use of menopausal hormone therapy.Natural and surgical premature menopause (before age 40 years) were associated with a small but statistically significant increased risk

2019 JAMA

38. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. Additional treatment options are needed for patients who do not achieve sufficient reduction in low-density lipoprotein cholesterol (LDL-C) level with available lipid-lowering therapies.To assess the efficacy of bempedoic acid vs placebo in patients at high cardiovascular risk receiving (...) maximally tolerated lipid-lowering therapy.Phase 3, randomized, double-blind, placebo-controlled clinical trial conducted at 91 clinical sites in North America and Europe from November 2016 to September 2018, with a final date of follow-up of September 22, 2018. A total of 779 patients with atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, or both met randomization criteria, which included LDL-C level 70 mg/dL (1.8 mmol/L) or greater while receiving maximally tolerated

2019 JAMA

39. Cardiovascular disease data and analysis: guide for health professionals

with cardiovascular disease ( for further information on cardiovascular disease conditions. can help healthcare professionals make decisions about how to improve local primary care. There is a pack with local , looking at coronary heart disease, diabetes, kidney disease and stroke. The profiles compare the subject that include information on the inpatient care of people with diabetes who are admitted to hospital for a range of footcare conditions. The profiles compare data from the subject Spending on care (...) Cardiovascular disease data and analysis: guide for health professionals Cardiovascular disease data and analysis: guide for health professionals - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Register by 26 November

2019 Public Health England

40. Comparison of Frequency of Atherosclerotic Cardiovascular Disease Events Among Primary and Secondary Prevention Subgroups of the Systolic Blood Pressure Intervention Trial (Abstract)

Comparison of Frequency of Atherosclerotic Cardiovascular Disease Events Among Primary and Secondary Prevention Subgroups of the Systolic Blood Pressure Intervention Trial The Pooled Cohort Equation (PCE) predicts 10-year risk of first-time atherosclerotic cardiovascular disease (ASCVD) events and was incorporated in analyses of a primary and secondary prevention population in the Systolic Blood Pressure Intervention Trial (SPRINT). Whether PCE enhances risk prediction among secondary

2019 EvidenceUpdates